Subsidiary of Shandong Jincheng Pharmaceutical Group (300233.SZ) plans to sell a drug production technology and the rights of the holder of the marketing license to Haemoni.

Shandong Jincheng Pharmaceutical Group (300233.SZ) announced that its wholly-owned subsidiary, Beijing Jincheng Tail Pharmaceutical Co., Ltd. (referred to as "Jincheng Tail"), intends to transfer its held "progesterone vaginal soft capsule production technology and marketing authorization holder rights" to Hemroni (Shanghai) Pharmaceutical Technology Co., Ltd. (referred to as "Hemroni"). Jincheng Tail legally holds the drug approval number for "Progesterone Vaginal Soft Capsules (trade name: Langyin Baofen)". After mutual agreement between the two parties, the total cost of the transfer of the target product (including taxes) is 50 million yuan. This equity transfer aligns with Jincheng Tail's overall product development strategy, will optimize its product structure, improve asset operation efficiency, and further optimize its asset structure.